US20120125331A1 - Dry powder inhaler with aeroelastic dispersion mechanism - Google Patents
Dry powder inhaler with aeroelastic dispersion mechanism Download PDFInfo
- Publication number
- US20120125331A1 US20120125331A1 US13/364,201 US201213364201A US2012125331A1 US 20120125331 A1 US20120125331 A1 US 20120125331A1 US 201213364201 A US201213364201 A US 201213364201A US 2012125331 A1 US2012125331 A1 US 2012125331A1
- Authority
- US
- United States
- Prior art keywords
- inhaler
- recesses
- chamber
- medicament
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940112141 dry powder inhaler Drugs 0.000 title claims abstract description 17
- 239000006185 dispersion Substances 0.000 title description 15
- 230000007246 mechanism Effects 0.000 title description 8
- 239000003814 drug Substances 0.000 claims abstract description 69
- 239000012530 fluid Substances 0.000 claims abstract description 11
- 238000004891 communication Methods 0.000 claims abstract description 10
- 230000004044 response Effects 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 64
- 239000012528 membrane Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 235000014676 Phragmites communis Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 29
- 239000003570 air Substances 0.000 description 13
- 239000002245 particle Substances 0.000 description 11
- 239000003607 modifier Substances 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 9
- 230000003434 inspiratory effect Effects 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 7
- 230000000241 respiratory effect Effects 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000009298 Trigla lyra Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940101532 meted Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0035—Piercing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0053—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal
- A61M15/0055—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal the used dosages being coiled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8275—Mechanical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Definitions
- the present invention is directed generally to inhalers, for example, dry powder inhalers, and methods of delivering a medicament to a patient. More particularly, the present invention is directed to dry powder inhalers having an aeroelastic dispersion mechanism.
- DPIs Dry powder inhalers
- pMDI pressurized meted dose inhaler
- the DPIs are configured to deliver a powdered drug or drug mixture that includes an excipient and/or other ingredients.
- many DPIs have operated passively, relying on the inspiratory effort of the patient to dispense the drug provided by the powder.
- this passive operation can lead to poor dosing uniformity since inspiratory capabilities can vary from patient to patient, and sometimes even use-to-use by the same patient, particularly if the patient is undergoing an asthmatic attack or respiratory-type ailment which tends to close the airway.
- known single and multiple dose DPI devices use: (a) individual pre-measured doses, such as capsules containing the drug, which can be inserted into the device prior to dispensing; or (b) bulk powder reservoirs which are configured to administer successive quantities of the drug to the patient via a dispensing chamber which dispenses the proper dose.
- individual pre-measured doses such as capsules containing the drug
- bulk powder reservoirs which are configured to administer successive quantities of the drug to the patient via a dispensing chamber which dispenses the proper dose.
- DPI devices desire to administer a uniform aerosol dispersion amount in a desired physical form (such as a particulate size) of the dry powder into a patient's airway and direct it to a desired deposit site. If the patient is unable to provide sufficient respiratory effort, the extent of drug penetration, especially to the lower portion of the airway, may be impeded. This may result in premature deposit of the powder in the patient's mouth or throat.
- a desired physical form such as a particulate size
- a number of obstacles can undesirably impact the performance of the DPI.
- the small size of the inhalable particles in the dry powder drug mixture can subject them to forces of agglomeration and/or cohesion (i.e., certain types of dry powders are susceptible to agglomeration, which is typically caused by particles of the drug adhering together), which can result in poor flow and non-uniform dispersion.
- many dry powder formulations employ larger excipient particles to promote flow properties of the drug.
- separation of the drug from the excipient, as well as the presence of agglomeration can require additional inspiratory effort, which, again, can impact the stable dispersion of the powder within the air stream of the patient. Unstable dispersions may inhibit the drug from reaching its preferred deposit/destination site and can prematurely deposit undue amounts of the drug elsewhere.
- U.S. Pat. No. 5,655,523 discloses and claims a dry powder inhalation device which has a deagglomeration-aerosolization plunger rod or biased hammer and solenoid.
- U.S. Pat. No. 3,948,264 discloses the use of a battery-powered solenoid buzzer to vibrate the capsule to effectuate the efficient release of the powder contained therein. Those devices are based on the proposition that the release of the dry powder can be effectively facilitated by the use of energy input independent of patient respiratory effort.
- U.S. Pat. No. 5,533,502 to Piper discloses and claims a powder inhaler using patient inspiratory efforts for generating a respirable aerosol.
- the Piper invention also includes a cartridge capable of rotating, holding the depressed wells or blisters defining the medicament holding receptacles.
- a spring-loaded carriage compresses the blister against conduits with sharp edges that puncture the blister to release the medication that is then entrained in air drawn in from the air inlet conduit so that aerosolized medication is emitted from the aerosol outlet conduit.
- Crowder et al. describe a dry powder inhaler in U.S. Pat. No. 6,889,690 comprising a piezoelectric polymer packaging in which the powder for aerosolization is simulated using non-linear signals determined a priori for specific powders.
- Dry powder inhalers have gained widespread use, particularly in the United States.
- the DPI market is estimated to be worth in excess of $4 billion.
- Dry powder inhalers have the added advantages of a wide range of doses that can be delivered, excellent stability of drugs in powder form (no refrigeration), ease of maintaining sterility, non-ozone depletion, and they require no press-and-breathe coordination.
- DPIs require considerable inspiratory effort to draw the powder formulation from the device to generate aerosols for efficient lung deposition (see FIG. 1 for an illustration of typical mechanism of powder dispersion for DPIs).
- Many patients particularly asthmatic patients, children, and elderly patients, which are important patient groups for respiratory disease, are not capable of such effort.
- approximately 60 L/min of airflow is required to effectively deaggregate the fine cohesive powder. All currently available DPIs suffer from this potential drawback.
- Turbuhaler® device (a common DPI), is not suitable for children because of the low flow achieved by this patient group (see Martonen T., Smyth H D C, Isaccs K., Burton R., “Issues in Drug Delivery: Dry Powder Inhaler Performance and Lung Deposition”: Respiratory Care. 2005, 50(9)).
- powder technology provides potential solutions for flow rate dependence of DPIs.
- the present disclosure describes exemplary dry powder inhalers and associated single or multi-dose packaging, which holds the compound to be delivered for inhalation as a dry powder.
- dry powder inhalers bridge the gap between passive devices and active devices.
- the inhalers are passive devices that operate using the energy generated by the patient inspiratory flow inhalation maneuver. However, the energy generated by airflow within the devices is focused on the powder by using oscillations induced by airflow across an aeroelastic element. In this way the inhalers can be “tuned” to disperse the powder most efficiently by adjusting the resonance frequencies of the elastic element to match the physicochemical properties of the powder.
- the airflow rate required to generate the appropriate oscillations within the device is minimized because some of the energy used to create the vibrations in the elastic element is pre-stored in the element in the form of elastic tension (potential energy).
- Inhaler performance may be tailored to the lung function of individual patients by modulating the elastic tension. Thus, even patients with poor lung function and those who have minimal capacity to generate airflow during inspiration will able to attain the flow rate required to induce oscillations in the elastic element.
- An exemplary embodiment of the invention comprises a dry powder inhaler with an integrated assisted dispersion system that is adjustable according to the patients' inspiratory capabilities and the adhesive/cohesive nature of the powder.
- the inhaler comprises an aeroelastic element that flutters or oscillates in response to airflow through the inhaler.
- the aeroelastic element provides concentrated energy of the airflow driven by the patient into the powder to be dispersed.
- the aeroelastic element is preferably a thin elastic membrane held under tension that reaches optimal vibrational response at low flow rates drawn through the inhaler by the patient.
- the aeroelastic element is preferably adjustable according to the patient's inspiratory capabilities and the adhesive/cohesive forces within the powder for dispersal.
- a tensioning assembly is configured to apply a first amount of tension to the aeroelastic element such that the aeroelastic element is capable of vibrating in response to airflow through the chamber so as to aerosolize the dose of powdered medicament.
- FIG. 1 illustrates airflow across an aeroelastic element in accordance with various aspects of the disclosure.
- FIG. 2 illustrates airflow past an airflow modifier and across an aeroelastic element in accordance with various aspects of the disclosure.
- FIG. 3A is a schematic representation of a top cross-sectional view of an exemplary inhaler in accordance with various aspects of the disclosure.
- FIG. 3B is a schematic representation of an end cross-sectional view of an exemplary inhaler in accordance with various aspects of the disclosure.
- FIG. 4 is a schematic representation of first and second rollers loaded with the aeroelastic membrane with axles in the center of the rollers in accordance with various aspects of the disclosure.
- FIG. 5 is representation of an exemplary dosing applicator in accordance with various aspects of the disclosure.
- FIG. 6 is a representation of another exemplary dosing applicator in accordance with various aspects of the disclosure.
- FIGS. 7A-7C are representations of an exemplary aeroelastic membrane and its relation to exemplary base clamps, upper clamps, and tensioning rods in accordance with various aspects of the disclosure.
- FIG. 8 is a representation of an exemplary dispensing mechanism in accordance with various aspects of the disclosure.
- FIG. 9 is a representation of an alternative exemplary dispensing mechanism in accordance with various aspects of the disclosure.
- FIG. 10 is a representation of an alternative exemplary dispensing mechanism in accordance with various aspects of the disclosure.
- the dry powder inhaler 100 may comprise a casing 102 having an outer wall 104 and two inner walls 106 , 108 .
- the inner walls 106 , 108 may extend in a first direction from a first inner surface 112 of the outer wall 104 toward a second inner surface 114 of the outer wall 104 .
- the inner walls 106 , 108 may also extend in a second direction from a proximal end 116 of the casing 102 to a distal end 118 of the casing 102 .
- the outer wall 104 and inner walls 106 , 108 may cooperate to define three chambers in the casing 102 .
- the three chambers may include a middle chamber 122 and two side chambers 124 , 126 located on opposite sides of the middle chamber 122 relative to one another.
- the side chambers may comprise a first side chamber 124 located to a first side of the middle chamber 122 and a second side chamber 126 located to a second side of the middle chamber 122 .
- the distal end 118 of the casing 102 may include one or more airflow inlets 128 providing fluid communication between the middle chamber 122 and ambient air outside the casing 102 .
- the proximal end 116 of the casing 102 may include a mouthpiece 130 .
- the mouthpiece 130 may a separate structure affixed to the outer wall 104 of the casing 102 , or the mouthpiece 130 and casing 102 may comprise a single piece of unitary construction.
- the mouthpiece 130 may include an opening 132 providing fluid communication between the middle chamber 122 and the outside of the casing 102 .
- the opening 132 may be shaped as an oval, a circle, a triangle, or any other desired shape.
- the mouthpiece 130 may have a shape that facilitates pursing of a patient's lips over the mouthpiece 130 and creating a seal between the lips and the mouthpiece 130 .
- the inhaler 100 may include a nozzle 134 between the middle chamber 122 and the opening 132 .
- the nozzle 134 may extend from the opening 132 , through the mouthpiece 130 , and into the middle chamber 122 .
- the nozzle 134 may comprise at least one helical tube 136 through which air and powder can be inhaled.
- the tube 136 can be configured to increase the turbulence in the air that flows through the nozzle 134 .
- An aeroelastic element 140 may extend across a center region 142 of the middle chamber 122 between the inner walls 106 , 108 .
- the aeroelastic element 140 may include one or more doses of a medicament 141 , for example, doses of powdered medicament, and the center region 142 may comprise a region for dispensing a dose of medicament into airflow through the inhaler 100 .
- the aeroelastic element 140 may comprise a membrane 144 , for example, a thin elastic membrane, wound between two spools 146 , 148 . An unused end of the membrane 144 may be wound on a first spool 146 , and a used end of the membrane 144 may be wound on a second spool 148 .
- the first spool 146 may be disposed about a first axle 147
- the second spool 148 may be disposed about a second axle 149 .
- the first spool 146 may be in the first side chamber 124
- the second spool 148 may be in the second side chamber 126 .
- the membrane 144 extends through a slot 150 in the inner wall 106 , across the center region 142 , and through a slot 152 in the inner wall 108 .
- the aeroelastic element 140 may comprise a membrane, a film, a reed, a sheet, a panel, or a blade.
- the aeroelastic element may be manufactured of materials comprising polymers, thin metals, polymer-coated metals, and/or metal-coated polymers.
- the inhaler 100 may include two base clamps 154 , 156 fixedly attached to a first inner surface 112 of the casing 102 .
- the base clamps 154 , 156 may be in the middle chamber 122 .
- a first of the base clamps 154 may be between the center region 142 and the first inner wall 106
- the second of the base clamps 156 may be between the center region 142 and the second inner wall 108 .
- the aeroelastic element 140 may rest on the base clamps 154 , 156 .
- the inhaler 100 may include two upper clamps 158 , 160 in the middle chamber 122 associated with the two base clamps 154 , 156 .
- a first upper clamp 158 may be on an opposite side of the aeroelastic element 140 relative to the first base clamp 154 and configured to descend atop the first base clamp 154 to sandwich the aeroelastic element therebetween.
- the second upper clamp 160 may be on an opposite side of the aeroelastic element 140 relative to the second base clamp 156 and configured to descend atop the second base clamp 156 to sandwich the aeroelastic element therebetween.
- the upper clamps 158 , 160 and base clamps 154 , 156 may hold the aeroelastic element 140 in place across the center region 142 with a desired amount of tension. The desired amount of tension may be determined based on a user's inhalation strength.
- the upper clamps may be fixedly attached to the second inner surface 114 of the casing 102 , and the base clamps may be configured to ascend toward the upper clamps to sandwich the aeroelastic element therebetween.
- a first of the base clamps 154 may be in the first side chamber 124 between the first spool 146 and the first wall 106
- the second of the base clamps 156 may be in the second side chamber 126 between the second spool 148 and the second wall 108 .
- the inhaler 100 may include an advancement member 162 extending outward of the casing 102 .
- the advancement member 162 may comprise, for example, a lever, a dial, or the like.
- the advancement member 162 may be mechanically coupled to the first and second upper clamps 158 , 160 via, for example, a crank 164 or other known linkage.
- the advancement member 162 and crank 164 are structured and arranged such that when the advancement member 162 is actuated by a user, the crank 164 is caused to move the upper clamps 158 , 160 in a direction away from the base clamps 154 , 156 .
- Actuation of the advancement member 162 may also cause the second axle 149 to turn in a manner that increases the used end of the aeroelastic element 140 wound thereon.
- the inhaler 100 may include one or more tensioning rods 166 , 168 configured to increase the tension of the aeroelastic element 140 beyond the tension applied by the base clamps 154 , 156 and upper clamps 158 , 160 .
- the tensioning rods 166 , 168 are between the first and second upper clamps 158 , 160 .
- the tensioning rods 166 , 168 may be mechanically coupled to the crank 164 such that actuation of the advancement member 162 causes the tensioning rods 166 , 168 to move in a direction away from the aeroelastic element 140 .
- one or more tension controllers 157 , 159 may be attached to one or both of the spool axles 147 , 149 , thus allowing the tension of the aeroelastic element 140 to be manually fixed and maintained across the spool axles 147 , 149 and obviating the need for tensioning rods.
- the amount tension applied by the clamps, tensioning rods, and/or tension controllers can be determined based on inhalation strength of a user.
- the second axle 149 associated with the second spool 148 may comprise a concentric spring 170 , which is mechanically coupled to the advancement member 162 so that actuation of the advancement member 162 results in the aeroelastic element 140 being transferred from the first spool 138 to the second spool 148 as the spring-loaded axle 149 is activated.
- the inhaler 100 may include a roller 172 ( FIG. 5 ) adjacent to the first spool 146 and engaging the aeroelastic element 140 , thereby resulting in additional tension in the aeroelastic element.
- a dose counter 174 may be mechanically coupled to the advancement member 162 in such a way that the dose counter 174 changes numbers by one each time the advancement member 162 is actuated.
- the dose counter 174 may be at an exterior surface of the casing 102 so as to be visible to a user.
- the dose counter 174 may be inside the casing 102 , but visible to a user via a transparent or translucent window (not shown), as would be understood by persons skilled in the art.
- the inhaler 100 may include a powder dose applicator 176 located between the first spool 146 and the first base clamp 154 .
- the powder dose applicator 176 may include a dispensing chute 178 filled with at least one dose of powder 180 .
- the dispensing chute 178 may include a top end 182 and a bottom end 184 .
- a wheel 186 may be at the bottom end of the dispensing chute 178 .
- the wheel 186 may be rotatable about an axle 188 .
- the axle 188 may be mechanically coupled to the advancement member 162 such that the wheel 186 rotates an amount sufficient to dispense one dose of powdered medicament to the aeroelastic element.
- the wheel 186 may include one or more notches 190 in its periphery, with the volume of each notch being sized for one dose of powdered medicament.
- the wheel shown in FIG. 5 may be replaced with a dispensing disk 686 , as shown in FIG. 6 .
- the dispensing chute 178 above the aeroelastic element 140 is filled with at least one dose of powdered medicament.
- the dispensing disk 686 may be located between the aeroelastic element 140 and the dispensing chute 178 and may be in contact with the bottom end 184 of the chute 178 .
- the disk 686 may further include multiple dispensing openings 690 clustered in one section of the disk 686 , for example, a periphery of the disk 686 .
- the dispensing openings 690 correspond to an accurate amount of powdered medicament to be dispensed as a dose.
- the dispensing disk 686 rotates about an axle 688 as the advancement member 162 is actuated, thereby resulting in an accurate amount of powdered medicament falling through the dispensing openings 690 and to the aeroelastic element 140 .
- the disk 686 may make one complete 360° rotation each time the advancement member 162 is actuated.
- the inhaler 100 may include blister strip packaging attached to the two spools in place of the powder dose applicators discussed above.
- the blister strip packaging 801 may include at least one individual dosing cup 803 .
- Each cup 803 may be filled with a dose of powdered medicament and covered by a peelable top layer.
- the dosing cups 803 may be arranged serially along the length of the packaging strip 801 .
- An aeroelastic element 840 may be stretched across the center region 142 and fixedly coupled to, for example, the inner walls or any other structure capable of maintaining the element 840 fixedly stretched across the center region 142 .
- the strip 801 may be in proximity to the aeroelastic element 840 in the center region 142 such that the aeroelastic element 840 may act as an actuator, making contact with the blister packaging and dispersing the powder dose when the aeroelastic element begins to vibrate during inhalation by a patient.
- a powder dose opener 805 may be configured to remove the top peelable layer from the blister strip packaging 801 for one dose when the blister strip 801 is advanced from the first spool to the second spool.
- the powder dose opener may alternatively be a simple puncturing device, such as a needle, that inserts small holes in the blister strip blister cavity, making the dose ready for inhalation.
- blister strip packaging 901 may include clusters 905 of multiple small dosing cups 903 for simultaneous multiple drug dosing, the clusters 905 may be arranged serially along the length of the blister strip 901 .
- the large arrows depict the direction of airflow across the blister strip and aeroelastic element.
- the small vertical arrows depict the vibrational motion of the aeroelastic element.
- the inhaler may include an aeroelastic element 1040 that may comprise, for example, an aeroelastic and deformable membrane.
- the element 1040 may include at least one individual dosing cup 1003 filled with a dose of powdered medicament in the form of blister strip packaging 1001 .
- the dosing cup 1003 may be configured to deform and raise the powder dose to the level of the surrounding element 1040 .
- the inhaler may comprise a single powder dose such that the inhaler may be disposed of after a single use.
- the inhaler 100 may include two rollers 192 , one above and one below the aeroelastic element 140 .
- the rollers 192 may be between the powder dose applicator 176 and the first base clamp 154 or between the powder dose applicator 176 and the inner wall 106 .
- the rollers 192 turn as the aeroelastic element 140 moves from the first spool 146 to the second spool 148 due to the frictional force applied by the aeroelastic element 140 as it is urged past the pinching rollers 192 .
- the rollers 192 fully engage the aeroelastic element 140 and flatten the powder deposited onto the aeroelastic element 140 and break up clumps in the powder.
- the advancement member 162 may be capable of turning the crank to release the upper clamps and tensioner rods, advancing the dose counter, turning the wheel in the dispensing chute, advancing the spring-loaded axle in the second spool by one position to advance the aeroelastic element a predetermined distance from the first spool to the second spool, and/or moving a dose of powder medicament into the center region 142 .
- the inhaler 100 may include one or more airflow modifiers 198 proximal of the one or more airflow inlets 128 and at a distal end of the center region 142 .
- the one or more airflow modifiers 198 may be distal of the center region 142 and/or at a distal portion within the center region 142 .
- the one or more airflow modifiers 198 may comprise multiple triangular rods extending from the first inner wall 106 to the second inner wall 108 . As air flows through the one or more airflow inlets 128 and toward the center region 142 , the one or more airflow modifiers 198 may cause vortices that allow air to pass above and below the modifiers.
- a method for dispensing powder by inhalation using any of the aforementioned exemplary dry powder inhaler apparatuses may begin with a patient actuating the advancement member.
- the patient may purse his/her lips around the mouthpiece and inhales.
- air is sucked into the inhaler through one or more airflow inlets at the distal end of the inhaler.
- the inhaled air flows over the airflow modifiers.
- the airflow then encounters the aeroelastic element, causing the element to vibrate or flutter and disperse a dose of powdered medicament from the element into the airflow.
- the combined flow of air and powder then flow into the distal end of the airflow nozzle and the mouthpiece.
- the combined flow of air and powder leave the mouthpiece and enter the patient's mouth and respiratory tract.
- the airflow modifiers and/or the helical shape of the nozzle may increase the turbulence of the airflow to better aerosolize and break up the powdered dose of medicament into smaller particles, thus maximizing the dose received by the patient and allowing the smaller particles to pass further into the respiratory tract.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A dry powder inhaler for delivering medicament to a patient includes a housing defining a chamber for receiving a dose of powdered medicament, an inhalation port in fluid communication with the chamber, at least one airflow inlet providing fluid communication between the chamber and an exterior of the housing, and an aeroelastic element in the chamber and associated with a dose of powdered medicament. A tensioning assembly is configured to apply a first amount of tension to the aeroelastic element such that the aeroelastic element is capable of vibrating in response to airflow through the chamber so as to aerosolize the dose of powdered medicament.
Description
- This application is a continuation-in-part of U.S. application Ser. No. 11/713,180, entitled “Dry Powder Inhaler with Aeroelastic Dispersion Mechanism,” filed on Mar. 2, 2007, pending, which claims the benefit of priority of U.S. provisional application No. 60/778,878, entitled “Dry Powder Inhaler with Aeroelastic Dispersion Mechanism,” filed on Mar. 3, 2006, the contents of both of which are incorporated herein by reference in their entirety.
- The present invention is directed generally to inhalers, for example, dry powder inhalers, and methods of delivering a medicament to a patient. More particularly, the present invention is directed to dry powder inhalers having an aeroelastic dispersion mechanism.
- Dry powder inhalers (“DPIs”) represent a promising alternative to pressurized meted dose inhaler (“pMDI”) devices for delivering drug aerosols without using CFC propellants. See generally, Crowder et al., 2001: an Odyssey in Inhaler Formulation and Design, Pharmaceutical Technology, pp. 99-113, July 2001; and Peart et al., New Developments in Dry Powder Inhaler Technology, American Pharmaceutical Review, Vol. 4, n,3, pp. 37-45 (2001). Martonen et al. 2005 Respiratory Care, Smyth and Hickey American Journal of Drug Delivery, 2005.
- Typically, the DPIs are configured to deliver a powdered drug or drug mixture that includes an excipient and/or other ingredients. Conventionally, many DPIs have operated passively, relying on the inspiratory effort of the patient to dispense the drug provided by the powder. Unfortunately, this passive operation can lead to poor dosing uniformity since inspiratory capabilities can vary from patient to patient, and sometimes even use-to-use by the same patient, particularly if the patient is undergoing an asthmatic attack or respiratory-type ailment which tends to close the airway.
- Generally described, known single and multiple dose DPI devices use: (a) individual pre-measured doses, such as capsules containing the drug, which can be inserted into the device prior to dispensing; or (b) bulk powder reservoirs which are configured to administer successive quantities of the drug to the patient via a dispensing chamber which dispenses the proper dose. See generally, Prime et al., Review of Dry Powder Inhaler's, 26 Adv. Drug Delivery Rev., pp. 51-58 (1997); and Hickey et al., A New Millennium for Inhaler Technology, 21 Pharm. Tech., n. 6, pp. 116-125 (1997).
- In operation, DPI devices desire to administer a uniform aerosol dispersion amount in a desired physical form (such as a particulate size) of the dry powder into a patient's airway and direct it to a desired deposit site. If the patient is unable to provide sufficient respiratory effort, the extent of drug penetration, especially to the lower portion of the airway, may be impeded. This may result in premature deposit of the powder in the patient's mouth or throat.
- A number of obstacles can undesirably impact the performance of the DPI. For example, the small size of the inhalable particles in the dry powder drug mixture can subject them to forces of agglomeration and/or cohesion (i.e., certain types of dry powders are susceptible to agglomeration, which is typically caused by particles of the drug adhering together), which can result in poor flow and non-uniform dispersion. In addition, as noted above, many dry powder formulations employ larger excipient particles to promote flow properties of the drug. However, separation of the drug from the excipient, as well as the presence of agglomeration, can require additional inspiratory effort, which, again, can impact the stable dispersion of the powder within the air stream of the patient. Unstable dispersions may inhibit the drug from reaching its preferred deposit/destination site and can prematurely deposit undue amounts of the drug elsewhere.
- A number of different inhalation devices have been designed to attempt to resolve problems attendant with conventional passive inhalers. For example, U.S. Pat. No. 5,655,523 discloses and claims a dry powder inhalation device which has a deagglomeration-aerosolization plunger rod or biased hammer and solenoid. U.S. Pat. No. 3,948,264 discloses the use of a battery-powered solenoid buzzer to vibrate the capsule to effectuate the efficient release of the powder contained therein. Those devices are based on the proposition that the release of the dry powder can be effectively facilitated by the use of energy input independent of patient respiratory effort.
- U.S. Pat. No. 5,533,502 to Piper discloses and claims a powder inhaler using patient inspiratory efforts for generating a respirable aerosol. The Piper invention also includes a cartridge capable of rotating, holding the depressed wells or blisters defining the medicament holding receptacles. A spring-loaded carriage compresses the blister against conduits with sharp edges that puncture the blister to release the medication that is then entrained in air drawn in from the air inlet conduit so that aerosolized medication is emitted from the aerosol outlet conduit.
- Crowder et al. describe a dry powder inhaler in U.S. Pat. No. 6,889,690 comprising a piezoelectric polymer packaging in which the powder for aerosolization is simulated using non-linear signals determined a priori for specific powders.
- In recent years, dry powder inhalers (DPIs) have gained widespread use, particularly in the United States. Currently, the DPI market is estimated to be worth in excess of $4 billion. Dry powder inhalers have the added advantages of a wide range of doses that can be delivered, excellent stability of drugs in powder form (no refrigeration), ease of maintaining sterility, non-ozone depletion, and they require no press-and-breathe coordination.
- There is great potential for delivering a number of therapeutic compounds via the lungs (see, for example, Martonen T., Smyth H D C, Isaccs K., Burton R., “Issues in Drug Delivery: Dry Powder Inhaler Performance and Lung Deposition”: Respiratory Care. 2005, 50(9); and Smyth H D C, Hickey, A J, “Carriers in Drug Powder Delivery: Implications for Inhalation System Design,” American Journal of Drug Delivery, 2005, 3(2),117-132). In the search for non-invasive delivery of biologics (which currently must be injected), it was realized that the large highly absorptive surface area of the lung with low metabolic drug degradation, could be used for systemic delivery of proteins such as insulin. The administration of small molecular weight drugs previously administered by injection is currently under investigation via the inhalation route either to provide non-invasive rapid onset of action, or to improve the therapeutic ratio for drugs acting in the lung (e.g. lung cancer).
- Gene therapy of pulmonary disease is still in its infancy but could provide valuable solutions to currently unmet medical needs. The recognition that the airways may provide a real opportunity for delivering biotech therapeutics in a non-invasive way was recently achieved with Exubera™, an inhaled insulin product. This product has obtained a recommendation for approval by US Food and Drug Administration and will lead to expanded opportunities for other biologics to be administered via the airways.
- Key to all inhalation dosage forms is the need to maximize the “respirable dose” (particles with aerodynamic diameters<5.0 μm that deposit in the lung) of a therapeutic agent. However, both propellant-based inhalers and current DPI systems only achieve lung deposition efficiencies of less than 20% of the delivered dose. The primary reason why powder systems have limited efficiency is the difficult balancing of particle size (particles under 5 μm diameter) and strong inter-particulate forces that prevent deaggregation of powders (strong cohesive forces begin to dominate at particle sizes<10 μm) (Smyth H D C., Hickey, A J., “Carriers in Drug Powder Delivery: Implications for inhalation System Design,” American Journal of Drug Delivery, 2005, 3(2), 117-132). Thus, DPIs require considerable inspiratory effort to draw the powder formulation from the device to generate aerosols for efficient lung deposition (see
FIG. 1 for an illustration of typical mechanism of powder dispersion for DPIs). Many patients, particularly asthmatic patients, children, and elderly patients, which are important patient groups for respiratory disease, are not capable of such effort. In most DPIs, approximately 60 L/min of airflow is required to effectively deaggregate the fine cohesive powder. All currently available DPIs suffer from this potential drawback. - Multiple studies have shown that the dose emitted from dry powder inhalers (DPI) is dependent on air flow rates (see Martonen T., Smyth H D C, Isaccs K., Burton R., “Issues in Drug Delivery: Dry Powder Inhaler Performance and Lung Deposition”: Respiratory Care. 2005, 50(9)). Increasing air-flow increases drug dispersion due to increases in drag forces of the fluid acting on the particle located in the flow. The Turbuhaler® device (a common DPI), is not suitable for children because of the low flow achieved by this patient group (see Martonen T., Smyth H D C, Isaccs K., Burton R., “Issues in Drug Delivery: Dry Powder Inhaler Performance and Lung Deposition”: Respiratory Care. 2005, 50(9)).
- Considerable intra-patient variability of inhalation rates has been found when patients inhale through two leading DPI devices. That inherent variability has prompted several companies to evaluate ways of providing energy in the inhaler (i.e. “active” DPIs). Currently, there is no active DPI commercially available. The active inhalers under investigation include technologies that use compressed air, piezoelectric actuators, and electric motors. The designs of those inhalers are very complex and utilize many moving parts and components. The complexity of those devices presents several major drawbacks including high cost, component failure risk, complex manufacturing procedures, expensive quality control, and difficulty in meeting specifications for regulatory approval and release (Food and Drug Administration).
- Alternatively, powder technology provides potential solutions for flow rate dependence of DPIs. For example, hollow porous microparticles having a geometric size of 5-30 μm, but aerodynamic sizes of 1-5 μm require less power for dispersion than small particles of the same mass. This may lead to flow independent drug dispersion but is likely to be limited to a few types of drugs with relevant physicochemical properties.
- Thus there are several problems associated with current dry powder inhaler systems including the most problematic issue: the dose a patient receives is highly dependent on the flow rate the patient can draw through the passive-dispersion device. Several patents describing potential solutions to this problem employ an external energy source to assist in the dispersion of powders and remove this dosing dependence on patient inhalation characteristics. Only one of these devices has made it to market or been approved by regulatory agencies such as the US Food and Drug Administration. Even upon approval, it is likely that these complex devices will have significant costs of manufacture and quality control, which could have a significant impact on the costs of drugs to patients.
- The present disclosure describes exemplary dry powder inhalers and associated single or multi-dose packaging, which holds the compound to be delivered for inhalation as a dry powder. These dry powder inhalers bridge the gap between passive devices and active devices. The inhalers are passive devices that operate using the energy generated by the patient inspiratory flow inhalation maneuver. However, the energy generated by airflow within the devices is focused on the powder by using oscillations induced by airflow across an aeroelastic element. In this way the inhalers can be “tuned” to disperse the powder most efficiently by adjusting the resonance frequencies of the elastic element to match the physicochemical properties of the powder. In addition, the airflow rate required to generate the appropriate oscillations within the device is minimized because some of the energy used to create the vibrations in the elastic element is pre-stored in the element in the form of elastic tension (potential energy). Inhaler performance may be tailored to the lung function of individual patients by modulating the elastic tension. Thus, even patients with poor lung function and those who have minimal capacity to generate airflow during inspiration will able to attain the flow rate required to induce oscillations in the elastic element.
- An exemplary embodiment of the invention comprises a dry powder inhaler with an integrated assisted dispersion system that is adjustable according to the patients' inspiratory capabilities and the adhesive/cohesive nature of the powder. The inhaler comprises an aeroelastic element that flutters or oscillates in response to airflow through the inhaler. The aeroelastic element provides concentrated energy of the airflow driven by the patient into the powder to be dispersed. The aeroelastic element is preferably a thin elastic membrane held under tension that reaches optimal vibrational response at low flow rates drawn through the inhaler by the patient. The aeroelastic element is preferably adjustable according to the patient's inspiratory capabilities and the adhesive/cohesive forces within the powder for dispersal.
- According to various aspects of the disclosure, a dry powder inhaler for delivering medicament to a patient includes a housing defining a chamber for receiving a dose of powdered medicament, an inhalation port in fluid communication with the chamber, at least one airflow inlet providing fluid communication between the chamber and an exterior of the housing, and an aeroelastic element in the chamber and associated with a dose of powdered medicament. A tensioning assembly is configured to apply a first amount of tension to the aeroelastic element such that the aeroelastic element is capable of vibrating in response to airflow through the chamber so as to aerosolize the dose of powdered medicament.
-
FIG. 1 illustrates airflow across an aeroelastic element in accordance with various aspects of the disclosure. -
FIG. 2 illustrates airflow past an airflow modifier and across an aeroelastic element in accordance with various aspects of the disclosure. -
FIG. 3A is a schematic representation of a top cross-sectional view of an exemplary inhaler in accordance with various aspects of the disclosure. -
FIG. 3B is a schematic representation of an end cross-sectional view of an exemplary inhaler in accordance with various aspects of the disclosure. -
FIG. 4 is a schematic representation of first and second rollers loaded with the aeroelastic membrane with axles in the center of the rollers in accordance with various aspects of the disclosure. -
FIG. 5 is representation of an exemplary dosing applicator in accordance with various aspects of the disclosure. -
FIG. 6 is a representation of another exemplary dosing applicator in accordance with various aspects of the disclosure. -
FIGS. 7A-7C are representations of an exemplary aeroelastic membrane and its relation to exemplary base clamps, upper clamps, and tensioning rods in accordance with various aspects of the disclosure. -
FIG. 8 is a representation of an exemplary dispensing mechanism in accordance with various aspects of the disclosure. -
FIG. 9 is a representation of an alternative exemplary dispensing mechanism in accordance with various aspects of the disclosure. -
FIG. 10 is a representation of an alternative exemplary dispensing mechanism in accordance with various aspects of the disclosure. - An exemplary embodiment of a
dry powder inhaler 100 is illustrated inFIGS. 3A and 3B . According to various aspects of the disclosure, thedry powder inhaler 100 may comprise acasing 102 having anouter wall 104 and twoinner walls inner walls inner surface 112 of theouter wall 104 toward a secondinner surface 114 of theouter wall 104. Theinner walls proximal end 116 of thecasing 102 to adistal end 118 of thecasing 102. Thus, according to various aspects, theouter wall 104 andinner walls casing 102. - According to some aspects, the three chambers may include a
middle chamber 122 and twoside chambers middle chamber 122 relative to one another. The side chambers may comprise afirst side chamber 124 located to a first side of themiddle chamber 122 and asecond side chamber 126 located to a second side of themiddle chamber 122. - In accordance with various aspects, the
distal end 118 of thecasing 102 may include one ormore airflow inlets 128 providing fluid communication between themiddle chamber 122 and ambient air outside thecasing 102. Theproximal end 116 of thecasing 102 may include amouthpiece 130. Themouthpiece 130 may a separate structure affixed to theouter wall 104 of thecasing 102, or themouthpiece 130 andcasing 102 may comprise a single piece of unitary construction. Themouthpiece 130 may include anopening 132 providing fluid communication between themiddle chamber 122 and the outside of thecasing 102. Theopening 132 may be shaped as an oval, a circle, a triangle, or any other desired shape. Themouthpiece 130 may have a shape that facilitates pursing of a patient's lips over themouthpiece 130 and creating a seal between the lips and themouthpiece 130. - The
inhaler 100 may include anozzle 134 between themiddle chamber 122 and theopening 132. According to various aspects, thenozzle 134 may extend from theopening 132, through themouthpiece 130, and into themiddle chamber 122. In some aspects, thenozzle 134 may comprise at least onehelical tube 136 through which air and powder can be inhaled. Thetube 136 can be configured to increase the turbulence in the air that flows through thenozzle 134. - An
aeroelastic element 140 may extend across acenter region 142 of themiddle chamber 122 between theinner walls aeroelastic element 140 may include one or more doses of amedicament 141, for example, doses of powdered medicament, and thecenter region 142 may comprise a region for dispensing a dose of medicament into airflow through theinhaler 100. According to some aspects, theaeroelastic element 140 may comprise amembrane 144, for example, a thin elastic membrane, wound between twospools membrane 144 may be wound on afirst spool 146, and a used end of themembrane 144 may be wound on asecond spool 148. Thefirst spool 146 may be disposed about afirst axle 147, and thesecond spool 148 may be disposed about asecond axle 149. Thefirst spool 146 may be in thefirst side chamber 124, and thesecond spool 148 may be in thesecond side chamber 126. In such an embodiment, themembrane 144 extends through aslot 150 in theinner wall 106, across thecenter region 142, and through a slot 152 in theinner wall 108. In accordance with some aspects, theaeroelastic element 140 may comprise a membrane, a film, a reed, a sheet, a panel, or a blade. The aeroelastic element may be manufactured of materials comprising polymers, thin metals, polymer-coated metals, and/or metal-coated polymers. - According to various aspects, the
inhaler 100 may include two base clamps 154, 156 fixedly attached to a firstinner surface 112 of thecasing 102. According to some aspects, the base clamps 154, 156 may be in themiddle chamber 122. A first of the base clamps 154 may be between thecenter region 142 and the firstinner wall 106, and the second of the base clamps 156 may be between thecenter region 142 and the secondinner wall 108. Theaeroelastic element 140 may rest on the base clamps 154, 156. Theinhaler 100 may include twoupper clamps middle chamber 122 associated with the two base clamps 154, 156. For example, a firstupper clamp 158 may be on an opposite side of theaeroelastic element 140 relative to thefirst base clamp 154 and configured to descend atop thefirst base clamp 154 to sandwich the aeroelastic element therebetween. Similarly, the secondupper clamp 160 may be on an opposite side of theaeroelastic element 140 relative to thesecond base clamp 156 and configured to descend atop thesecond base clamp 156 to sandwich the aeroelastic element therebetween. The upper clamps 158, 160 and base clamps 154, 156 may hold theaeroelastic element 140 in place across thecenter region 142 with a desired amount of tension. The desired amount of tension may be determined based on a user's inhalation strength. It should be appreciated that in some aspects, the upper clamps may be fixedly attached to the secondinner surface 114 of thecasing 102, and the base clamps may be configured to ascend toward the upper clamps to sandwich the aeroelastic element therebetween. - In an alternative embodiment (not shown), a first of the base clamps 154 may be in the
first side chamber 124 between thefirst spool 146 and thefirst wall 106, and the second of the base clamps 156 may be in thesecond side chamber 126 between thesecond spool 148 and thesecond wall 108. - The
inhaler 100 may include anadvancement member 162 extending outward of thecasing 102. Theadvancement member 162 may comprise, for example, a lever, a dial, or the like. Theadvancement member 162 may be mechanically coupled to the first and secondupper clamps advancement member 162 and crank 164 are structured and arranged such that when theadvancement member 162 is actuated by a user, thecrank 164 is caused to move theupper clamps advancement member 162 may also cause thesecond axle 149 to turn in a manner that increases the used end of theaeroelastic element 140 wound thereon. - According to some exemplary aspects, as shown in
FIGS. 7A-7C , theinhaler 100 may include one ormore tensioning rods aeroelastic element 140 beyond the tension applied by the base clamps 154, 156 andupper clamps rods upper clamps rods advancement member 162 causes thetensioning rods aeroelastic element 140. When theadvancement member 162 is released or unactuated, the tensioningrods aeroelastic element 140. It should be appreciated that in some aspects, one ormore tension controllers 157, 159 (FIG. 4 ) may be attached to one or both of thespool axles aeroelastic element 140 to be manually fixed and maintained across thespool axles - Referring again to
FIG. 3B , in various aspects, thesecond axle 149 associated with thesecond spool 148 may comprise aconcentric spring 170, which is mechanically coupled to theadvancement member 162 so that actuation of theadvancement member 162 results in theaeroelastic element 140 being transferred from the first spool 138 to thesecond spool 148 as the spring-loadedaxle 149 is activated. Theinhaler 100 may include a roller 172 (FIG. 5 ) adjacent to thefirst spool 146 and engaging theaeroelastic element 140, thereby resulting in additional tension in the aeroelastic element. - According to some aspects, for example, inhalers having an aeroelastic element with multiple doses of medicament, a
dose counter 174 may be mechanically coupled to theadvancement member 162 in such a way that the dose counter 174 changes numbers by one each time theadvancement member 162 is actuated. In some aspects, thedose counter 174 may be at an exterior surface of thecasing 102 so as to be visible to a user. In some aspects, thedose counter 174 may be inside thecasing 102, but visible to a user via a transparent or translucent window (not shown), as would be understood by persons skilled in the art. - According to various aspects, as shown in
FIG. 5 , theinhaler 100 may include apowder dose applicator 176 located between thefirst spool 146 and thefirst base clamp 154. In some aspects, thepowder dose applicator 176 may include a dispensingchute 178 filled with at least one dose ofpowder 180. The dispensingchute 178 may include atop end 182 and abottom end 184. Awheel 186 may be at the bottom end of the dispensingchute 178. Thewheel 186 may be rotatable about anaxle 188. Theaxle 188 may be mechanically coupled to theadvancement member 162 such that thewheel 186 rotates an amount sufficient to dispense one dose of powdered medicament to the aeroelastic element. For example, thewheel 186 may include one ormore notches 190 in its periphery, with the volume of each notch being sized for one dose of powdered medicament. - According to some aspects, the wheel shown in
FIG. 5 may be replaced with adispensing disk 686, as shown inFIG. 6 . For example, the dispensingchute 178 above theaeroelastic element 140 is filled with at least one dose of powdered medicament. Thedispensing disk 686 may be located between theaeroelastic element 140 and the dispensingchute 178 and may be in contact with thebottom end 184 of thechute 178. Thedisk 686 may further include multiple dispensingopenings 690 clustered in one section of thedisk 686, for example, a periphery of thedisk 686. The dispensingopenings 690 correspond to an accurate amount of powdered medicament to be dispensed as a dose. Thedispensing disk 686 rotates about anaxle 688 as theadvancement member 162 is actuated, thereby resulting in an accurate amount of powdered medicament falling through the dispensingopenings 690 and to theaeroelastic element 140. For example, thedisk 686 may make one complete 360° rotation each time theadvancement member 162 is actuated. - In various aspects, the
inhaler 100 may include blister strip packaging attached to the two spools in place of the powder dose applicators discussed above. For example, as shown inFIG. 8 , theblister strip packaging 801 may include at least oneindividual dosing cup 803. Eachcup 803 may be filled with a dose of powdered medicament and covered by a peelable top layer. The dosing cups 803 may be arranged serially along the length of thepackaging strip 801. Anaeroelastic element 840 may be stretched across thecenter region 142 and fixedly coupled to, for example, the inner walls or any other structure capable of maintaining theelement 840 fixedly stretched across thecenter region 142. Thestrip 801 may be in proximity to theaeroelastic element 840 in thecenter region 142 such that theaeroelastic element 840 may act as an actuator, making contact with the blister packaging and dispersing the powder dose when the aeroelastic element begins to vibrate during inhalation by a patient. Apowder dose opener 805 may be configured to remove the top peelable layer from theblister strip packaging 801 for one dose when theblister strip 801 is advanced from the first spool to the second spool. The powder dose opener may alternatively be a simple puncturing device, such as a needle, that inserts small holes in the blister strip blister cavity, making the dose ready for inhalation. - In some embodiments, as shown in
FIG. 9 ,blister strip packaging 901 may includeclusters 905 of multiplesmall dosing cups 903 for simultaneous multiple drug dosing, theclusters 905 may be arranged serially along the length of theblister strip 901. The large arrows depict the direction of airflow across the blister strip and aeroelastic element. The small vertical arrows depict the vibrational motion of the aeroelastic element. In various embodiments, as shown inFIG. 10 , the inhaler may include anaeroelastic element 1040 that may comprise, for example, an aeroelastic and deformable membrane. Theelement 1040 may include at least oneindividual dosing cup 1003 filled with a dose of powdered medicament in the form ofblister strip packaging 1001. Thedosing cup 1003 may be configured to deform and raise the powder dose to the level of thesurrounding element 1040. - It should be appreciated that the inhaler may comprise a single powder dose such that the inhaler may be disposed of after a single use.
- Referring again to
FIG. 5 , in some aspects, theinhaler 100 may include tworollers 192, one above and one below theaeroelastic element 140. Therollers 192 may be between thepowder dose applicator 176 and thefirst base clamp 154 or between thepowder dose applicator 176 and theinner wall 106. Therollers 192 turn as theaeroelastic element 140 moves from thefirst spool 146 to thesecond spool 148 due to the frictional force applied by theaeroelastic element 140 as it is urged past the pinchingrollers 192. Therollers 192 fully engage theaeroelastic element 140 and flatten the powder deposited onto theaeroelastic element 140 and break up clumps in the powder. - Thus, the
advancement member 162 may be capable of turning the crank to release the upper clamps and tensioner rods, advancing the dose counter, turning the wheel in the dispensing chute, advancing the spring-loaded axle in the second spool by one position to advance the aeroelastic element a predetermined distance from the first spool to the second spool, and/or moving a dose of powder medicament into thecenter region 142. - Referring again to
FIGS. 3A and 3B , according to various aspects, theinhaler 100 may include one ormore airflow modifiers 198 proximal of the one ormore airflow inlets 128 and at a distal end of thecenter region 142. It should be appreciated that the one ormore airflow modifiers 198 may be distal of thecenter region 142 and/or at a distal portion within thecenter region 142. In some aspects, the one ormore airflow modifiers 198 may comprise multiple triangular rods extending from the firstinner wall 106 to the secondinner wall 108. As air flows through the one ormore airflow inlets 128 and toward thecenter region 142, the one ormore airflow modifiers 198 may cause vortices that allow air to pass above and below the modifiers. - Referring now to
FIG. 1 , airflow at velocity V over an aeroelastic element under tension is illustrated. As shown, the airflow may result in flutter or vibration of theaeroelastic element 140. The vibration is represented by vertical arrows, and the airflow is represented by horizontal arrows.FIG. 2 illustrates the airflow at velocity V past an airflow modifier prior to encountering anaeroelastic element 140. As shown, the airflow modifier introduces turbulence into the airflow, thus increasing the vibration or flutter of the aeroelastic element for a given inhalation strength. - In operation, a method for dispensing powder by inhalation using any of the aforementioned exemplary dry powder inhaler apparatuses may begin with a patient actuating the advancement member. The patient may purse his/her lips around the mouthpiece and inhales. As the patient inhales, air is sucked into the inhaler through one or more airflow inlets at the distal end of the inhaler. The inhaled air flows over the airflow modifiers. The airflow then encounters the aeroelastic element, causing the element to vibrate or flutter and disperse a dose of powdered medicament from the element into the airflow. The combined flow of air and powder then flow into the distal end of the airflow nozzle and the mouthpiece. The combined flow of air and powder leave the mouthpiece and enter the patient's mouth and respiratory tract. The airflow modifiers and/or the helical shape of the nozzle may increase the turbulence of the airflow to better aerosolize and break up the powdered dose of medicament into smaller particles, thus maximizing the dose received by the patient and allowing the smaller particles to pass further into the respiratory tract.
- It will be apparent to those skilled in the art that various modifications and variations can be made in the inhalers and methods of the present disclosure without departing from the scope of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only.
Claims (20)
1-20. (canceled)
21. A dry powder inhaler for delivering medicament to a patient, the inhaler comprising:
a housing defining a chamber for receiving a dose of powdered medicament;
an inhalation port in fluid communication with the chamber;
at least one airflow inlet providing fluid communication between the chamber and an exterior of the housing; and
a strip of material having a generally flat top surface, a generally flat bottom surface, and a plurality of recesses in the top surface, wherein the recesses are each configured to hold a metered dosage of a powdered medicament, the strip of material being positioned between the inhalation port and the at least one airflow inlet such that a flow of air generated by a user via the inhalation port is configured to move the medicament that is released from one of the recesses through the chamber as an aerosolized dose.
22. An inhaler as in claim 21 , wherein the recesses are cup shaped in geometry.
23. An inhaler as in claim 21 , wherein the recesses are serially aligned along the strip.
24. An inhaler as in claim 21 , further comprising an actuator that is actuatable to make contact with the strip of material to thereby disperse the medicament from the recess.
25. An inhaler as in claim 24 , wherein the actuator is actuatable by the user inhalation that causes air to act on the actuator.
26. The inhaler of claim 24 , wherein the actuator comprises an aeroelastic element, and further comprising at least one tensioning member configured to hold the aeroelastic element at a tension that produces a desired vibrational response to airflow ranges of a patient.
27. The inhaler of claim 26 , wherein the tensioning member is adjustable to change the desired vibrational response.
28. The inhaler of claim 24 , wherein the actuator comprises one of a membrane, a reed, a sheet, a panel, and a blade.
29. The inhaler of claim 24 , wherein the actuator is made of a material comprising at least one of a polymer, a metal, and a metal-coated polymer.
30. The inhaler of claim 24 , further comprising a powder dose applicator, the powder dose applicator being configured to dispense the dose of powdered medicament to the recesses prior to inhalation by a patient.
31. The inhaler of claim 21 , further comprising:
a mouthpiece including the inhalation port; and
a nozzle between the chamber and the inhalation port.
32. The inhaler of claim 21 , wherein the inhalation port is at a first end of the housing and said at least one airflow inlet is at a second end of the housing substantially opposite the first end of the housing.
33. A method for delivering medicament to a patient comprising:
providing an inhaler comprising a housing defining a chamber, an inhalation port in fluid communication with the chamber, and at least one airflow inlet providing fluid communication between the chamber and an exterior of the housing;
providing a strip of material having a generally flat top surface, a generally flat bottom surface, and a plurality of recesses in the top surface, wherein the recesses each hold a metered dosage of a powdered medicament, wherein the strip of material is positioned between the inhalation port and the at least one airflow inlet; and
inhaling from the inhalation port to draw the medicament that is released from one of the recesses through the chamber as an aerosolized dose.
34. A method as in claim 33 , further comprising contacting the strip to dispense the medicament from the recess.
35. A method as in claim 34 , wherein the inhaler includes an actuator, and wherein inhaling from the inhalation port actuates the actuator to contact the strip.
36. A method for metering dosages of a dry powder medicament, the method comprising:
providing a strip of material having a generally flat top surface, a generally flat bottom surface, and a plurality of recesses in the top surface, wherein the recesses are each configured to hold a metered dosage of a powdered medicament, the strip of material being configured to be positioned within an inhaler such that a flow of air generated by a user via an inhalation port of the inhaler is configured to aerosolize the powdered medicament; and
using a powder dose applicator, dispensing a dose of powdered medicament to the recesses.
37. A method as in claim 36 , wherein the powder dose applicator comprises a dispensing chute having a top end and a bottom end, and a wheel at the bottom end, and further comprising rotating the wheel to dispense the powder from the bottom end and into one of the recesses.
38. A method as in claim 36 , wherein the recesses are cup shaped in geometry.
39. A method as in claim 36 , wherein the recesses are serially aligned along the strip, and further comprising advancing the strip and dispensing powder into the next recess.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/364,201 US20120125331A1 (en) | 2006-03-03 | 2012-02-01 | Dry powder inhaler with aeroelastic dispersion mechanism |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77887806P | 2006-03-03 | 2006-03-03 | |
US11/713,180 US20070209661A1 (en) | 2006-03-03 | 2007-03-02 | Dry powder inhaler with aeroelastic dispersion mechanism |
US12/246,116 US8127763B2 (en) | 2006-03-03 | 2008-10-06 | Dry powder inhaler with aeroelastic dispersion mechanism |
US13/364,201 US20120125331A1 (en) | 2006-03-03 | 2012-02-01 | Dry powder inhaler with aeroelastic dispersion mechanism |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/246,116 Continuation US8127763B2 (en) | 2006-03-03 | 2008-10-06 | Dry powder inhaler with aeroelastic dispersion mechanism |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120125331A1 true US20120125331A1 (en) | 2012-05-24 |
Family
ID=40532977
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/246,116 Active 2028-09-07 US8127763B2 (en) | 2006-03-03 | 2008-10-06 | Dry powder inhaler with aeroelastic dispersion mechanism |
US13/364,201 Abandoned US20120125331A1 (en) | 2006-03-03 | 2012-02-01 | Dry powder inhaler with aeroelastic dispersion mechanism |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/246,116 Active 2028-09-07 US8127763B2 (en) | 2006-03-03 | 2008-10-06 | Dry powder inhaler with aeroelastic dispersion mechanism |
Country Status (1)
Country | Link |
---|---|
US (2) | US8127763B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3519025A4 (en) * | 2016-09-30 | 2020-08-26 | De Motu Cordis Pty Ltd | Delivery device and associated methods of use |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1993645A4 (en) * | 2006-03-03 | 2011-05-18 | Stc Unm | Dry powder inhaler with aeroelastic dispersion mechanism |
US8127763B2 (en) * | 2006-03-03 | 2012-03-06 | Stc.Unm | Dry powder inhaler with aeroelastic dispersion mechanism |
IL191190A0 (en) * | 2008-05-01 | 2009-08-03 | Dan Adler | Dry powder inhaler |
US8985102B2 (en) | 2009-05-18 | 2015-03-24 | Adamis Pharmaceuticals Corporation | Dry powder inhalers |
CA2779488A1 (en) * | 2009-11-12 | 2011-05-19 | Stc.Unm | Dry powder inhaler with flutter dispersion member |
DK2515977T3 (en) | 2009-12-26 | 2018-04-16 | Inspiro Medical Ltd | DEVICE FOR DELIVERY OF DRY POWDER |
EP3431128A1 (en) | 2010-01-05 | 2019-01-23 | MicroDose Therapeutx, Inc. | Inhalation device and method |
EP2362796A4 (en) * | 2010-01-27 | 2014-10-08 | Aespira Ltd | Dry powder inhaler |
US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
TR201807942T4 (en) | 2012-09-26 | 2018-06-21 | Boehringer Ingelheim Int | Inhalers. |
US8845578B2 (en) | 2013-02-28 | 2014-09-30 | Medtronic Xomed, Inc. | Biomaterial delivery device |
US8920364B2 (en) | 2013-02-28 | 2014-12-30 | Medtronic Xomed, Inc. | Biomaterial delivery device |
NO2709641T3 (en) | 2014-03-10 | 2018-05-12 | ||
JP2018501903A (en) | 2015-01-14 | 2018-01-25 | レスピラ セラピューティクス インコーポレイテッドRespira Therapeutics,Inc. | Powder dispersion method and apparatus |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447151A (en) * | 1990-10-04 | 1995-09-05 | Valois | Powder inhaler with suction actuated locking means |
US6880555B1 (en) * | 1999-10-12 | 2005-04-19 | Shl Medical Ab | Inhaler |
US8127763B2 (en) * | 2006-03-03 | 2012-03-06 | Stc.Unm | Dry powder inhaler with aeroelastic dispersion mechanism |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1182779A (en) | 1966-09-17 | 1970-03-04 | Fisons Pharmaceuticals Ltd | Inhalation Device |
US3888253A (en) | 1972-08-04 | 1975-06-10 | Beecham Group Ltd | Device for administration of medicines |
GB1392945A (en) | 1972-08-23 | 1975-05-07 | Fisons Ltd | Inhalation device |
GB1459426A (en) | 1973-02-26 | 1976-12-22 | Allen & Hanburys Ltd | Inhalation devices |
US3948264A (en) | 1975-05-21 | 1976-04-06 | Mead Johnson & Company | Inhalation device |
GB1518998A (en) * | 1975-08-28 | 1978-07-26 | Gillette Co | Packaging flowable materials |
NO166268C (en) * | 1985-07-30 | 1991-07-03 | Glaxo Group Ltd | DEVICE FOR ADMINISTRATING PATIENTS TO PATIENTS. |
JPS62204756A (en) * | 1986-03-04 | 1987-09-09 | 大研医工株式会社 | Drug volatilizing method and apparatus |
SE453566B (en) | 1986-03-07 | 1988-02-15 | Draco Ab | POWDER INHALATOR DEVICE |
GB8909891D0 (en) * | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
EP0470154B1 (en) | 1989-04-28 | 1996-06-05 | Riker Laboratories, Inc. | Dry powder inhalation device |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
SK280968B6 (en) * | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Medicament pack for use in an inhalation device |
US5743250A (en) * | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
US5372128A (en) | 1993-04-14 | 1994-12-13 | Habley Medical Technology Corporation | Fluidizing powder inhaler |
US5533502A (en) | 1993-05-28 | 1996-07-09 | Vortran Medical Technology, Inc. | Powder inhaler with aerosolization occurring within each individual powder receptacle |
GB9312984D0 (en) * | 1993-06-23 | 1993-08-04 | Bespak Plc | Atomising dispenser |
SE9302550D0 (en) | 1993-07-30 | 1993-07-30 | Ernst Hoerlin | POWDER INHALES |
GB9417399D0 (en) * | 1994-08-30 | 1994-10-19 | Scherer Corp R P | Ocular treatment device |
US5622166A (en) | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US5692496A (en) * | 1995-08-02 | 1997-12-02 | Innovative Devices, Llc | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
TW469832U (en) | 1997-03-14 | 2001-12-21 | Astra Ab | Inhalation device |
GB9810126D0 (en) | 1998-05-13 | 1998-07-08 | Glaxo Group Ltd | |
GB0026647D0 (en) | 2000-10-31 | 2000-12-13 | Glaxo Group Ltd | Medicament dispenser |
US6626173B2 (en) | 2001-01-08 | 2003-09-30 | Iep Pharmaceutical Devices Inc. | Dry powder inhaler |
EP1416990A1 (en) | 2001-08-09 | 2004-05-12 | Glaxo Group Limited | Inhalation device with a pharmaceutical composition |
GB0120018D0 (en) * | 2001-08-16 | 2001-10-10 | Meridica Ltd | Pack containing medicament and dispensing device |
US6779520B2 (en) | 2001-10-30 | 2004-08-24 | Iep Pharmaceutical Devices Inc. | Breath actuated dry powder inhaler |
SE524957C2 (en) | 2002-04-12 | 2004-11-02 | Microdrug Ag | Method for dividing and distributing in air of dry powder drug |
US6889690B2 (en) | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
MXPA06008621A (en) | 2004-02-06 | 2007-03-27 | Microdose Technologies Inc | A blister pack for use with an inhalation device. |
AU2007210177C1 (en) | 2006-01-31 | 2012-11-01 | Oriel Therapeutics, Inc. | Dry powder inhalers having spiral travel paths, unit dose microcartridges with dry powder, related devices and methods |
EP1993645A4 (en) * | 2006-03-03 | 2011-05-18 | Stc Unm | Dry powder inhaler with aeroelastic dispersion mechanism |
-
2008
- 2008-10-06 US US12/246,116 patent/US8127763B2/en active Active
-
2012
- 2012-02-01 US US13/364,201 patent/US20120125331A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447151A (en) * | 1990-10-04 | 1995-09-05 | Valois | Powder inhaler with suction actuated locking means |
US6880555B1 (en) * | 1999-10-12 | 2005-04-19 | Shl Medical Ab | Inhaler |
US8127763B2 (en) * | 2006-03-03 | 2012-03-06 | Stc.Unm | Dry powder inhaler with aeroelastic dispersion mechanism |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3519025A4 (en) * | 2016-09-30 | 2020-08-26 | De Motu Cordis Pty Ltd | Delivery device and associated methods of use |
Also Published As
Publication number | Publication date |
---|---|
US20090095294A1 (en) | 2009-04-16 |
US8127763B2 (en) | 2012-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8127763B2 (en) | Dry powder inhaler with aeroelastic dispersion mechanism | |
CA2644679C (en) | Dry powder inhaler with aeroelastic dispersion mechanism | |
Ibrahim et al. | Inhalation drug delivery devices: technology update | |
US5027806A (en) | Medication delivery system phase two | |
US7461649B2 (en) | Portable gas operating inhaler | |
US8210171B2 (en) | Tubular dry powder drug containment systems, associated inhalers and methods | |
AU2003222538B2 (en) | Therapeutic dry powder preparation | |
US7246617B1 (en) | Inhalers | |
AU2007214748B2 (en) | Dry powder inhaler device | |
US20080115785A1 (en) | Inhalers | |
US9492625B2 (en) | Dry powder inhaler with flutter dispersion member | |
US20100154794A1 (en) | Inhaler Flow Channel | |
WO2005041848A2 (en) | Dry powder drug containment system packages with tabs, inhalers and associated methods | |
JPH06509958A (en) | powder dispenser | |
CA2549174C (en) | Portable gas operating inhaler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF NEW MEXICO, NEW MEXIC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SMYTH, HUGH D.C.;TRUMAN, CHARLES RANDALL;SIGNING DATES FROM 20080324 TO 20080407;REEL/FRAME:027709/0972 |
|
AS | Assignment |
Owner name: STC.UNM, NEW MEXICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF NEW MEXICO;REEL/FRAME:027720/0229 Effective date: 20090113 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |